Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Bears Are Devouring Spectrum Pharmaceuticals, Inc. (NSPPI)

Just 10 days ago, I examined the bear thesis on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) as, amazingly, over half of its float was sold short. It looks like those short sellers were on to something after all.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) tonight announced a crushing 40% guidance reduction for 2013, setting a revenue target between $160 million to $180 million, compared to Wall Street’s roughly $300 million estimate. The stock is currently down nearly 40% in after-hours trading. The culprit is steeply lower Fusilev sales, a branded drug that took full advantage of generic leucovorin’s unavailability to rack up $204 million in 2012 sales. Short sellers saw this as just a temporary bonanza while bullish investors believed that Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) could hold on to those market share gains.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).The announcement is a dramatic change of tune from Feb. 21, when during Spectrum’s fourth-quarter conference call CEO Rajesh Shrotriya confidently declared, “We expect 2013 revenues to grow” on the back of strong January trends. I’m guessing February and March were trending worse than Seth MacFarlane’s Oscar performance.

Perhaps putting too much faith in management’s comments from the conference call, I concluded my video from earlier this month that while the growth days of Fusilev were over, generics weren’t poised to immediately decimate its market share. Oops. However, I did at least argue that, over the longer haul, short sellers would be vindicated, potentially sooner if insurance reimbursement pressure hastened the switch to lower-cost generics from companies such as Sagent Pharmaceuticals Inc (NASDAQ:SGNT) .

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s valuation may be shattered, but it doesn’t mean the stock is finished. Fusilev is still expected to bring in $85 million in 2013. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)also has two other drugs on the market, albeit neither are great sellers, a handful of phase 2 and phase 3 cancer assets, and about $60 million in net cash to help develop them.

Even for investors who believe in those late-stage assets, the valuation of this company is still murky given that Fusilev sales could decline worse than estimated. I recommend staying away from falling knife stocks, unless you like getting cut.

The article Why Bears Are Devouring Spectrum originally appeared on Fool.com and is written by David Williamson

David Williamson has no position in any stocks mentioned, and neither does The Motley Fool. Follow David on Twitter @MotleyDavid.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!